Press release: STADA appoints Christos Gallis as Head of Eastern Europe
- Photo Info
- Download
One document
STADA appoints Christos Gallis as Head of Eastern Europe
- Christos Gallis will assume the role of Head of Eastern Europe, effective 1 July 2023
- Gallis, who currently heads STADA’s South-Eastern and Eastern Europe cluster, will be responsible for STADA’s activities in Serbia & West Balkans, Ukraine, Poland, Czech Republic, Slovakia, Bulgaria, Romania, Croatia, Slovenia, Greece, Hungary, Israel, Cyprus, the Baltic States and the Eurasia region
- STADA CEO Peter Goldschmidt: “Since joining STADA in 2019, Christos has shown himself to be a mature and thoughtful leader of his South-Eastern and Eastern cluster, guiding these markets to substantial growth and successfully integrating both the Walmark vitamins, minerals and supplements business, and the consumer healthcare brands gained through transactions with GSK and Sanofi.”
Bad Vilbel – 15 June 2023 – STADA has named Christos Gallis as Head of Eastern Europe, effective 1 July 2023. From the same date, Gallis will also become a member of the STADA Executive Committee, which consists of board members as well as executive vice-presidents of important business functions, representing all geographies of the STADA Group. He will be based at STADA’s headquarters in Bad Vilbel, Germany, and will report directly to CEO Peter Goldschmidt.
In his new role, Gallis will assume responsibility for STADA’s operations in Serbia and the West Balkans, Ukraine, Poland, Czech Republic, Slovakia, Bulgaria, Romania, Croatia, Slovenia, Greece, Hungary, Israel, Cyprus, the Baltic States and the Eurasia region encompassing several Commonwealth of Independent States (CIS) countries. Western European countries, such as France, Germany, Italy and the UK, as well as Russia, will continue to be led by Stephan Eder. Stephane Jacqmin continues to head STADA’s business in the Middle East, Africa and Asia.
“Since joining STADA in 2019,“ Goldschmidt stated, “Christos has shown himself to be a mature and thoughtful leader of his South-Eastern and Eastern Cluster, guiding these markets to substantial growth and successfully integrating both the Walmark vitamins, minerals and supplements business, and the consumer healthcare brands gained through transactions with GSK and Sanofi. I would like to thank Stephan for leading the Eastern European region very successfully at the STADA Executive Committee level for the past year, on top of his current role, and I’m happy he can now fully focus on the growth agenda in all our Western European markets.”
A Greek national, Gallis has worked in several countries, including Germany, Czech Republic and Vietnam. Before joining STADA, he spent 10 years at Sandoz, having previously worked at Johnson and Johnson in several leading country head and sales and marketing roles.
“The growth journey that started 4-5 years ago in Eastern Europe will be further accelerated,” Gallis pledged. “My goal is to be the growth leader in these countries and outgrow competition. To join the STADA Executive Committee, and contribute to this, means nothing else than serving as an ambassador of the countries for which I am responsible, while always acting according to our company’s purpose of Caring for People’s Health as a Trusted Partner.”
About STADA Arzneimittel AG
STADA Arzneimittel AG is headquartered in Bad Vilbel, Germany. The company focuses on a three-pillar strategy consisting of consumer healthcare products, generics and specialty pharma. Worldwide, STADA Arzneimittel AG sells its products in approximately 120 countries. In financial year 2022, STADA achieved group sales of EUR 3,797.2 million and reported earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 884.7 million. As of 31 December 2022, STADA employed 13,183 people worldwide.
Additional information for journalists:
STADA Arzneimittel AG - Media Relations Stadastrasse 2-18 61118 Bad Vilbel - Germany Phone: +49 (0) 6101 603-165 E-Mail: press@stada.de Or visit us on the Internet at www.stada.com/press Follow STADA on LinkedIn, Twitter and Instagram
Additional information for capital market participants:
STADA Arzneimittel AG - Investor & Creditor Relations Stadastrasse 2-18 61118 Bad Vilbel – Germany Phone: +49 (0) 6101 603-4689 Fax: +49 (0) 6101 603-215 E-mail: ir@stada.de Or visit us on the Internet at www.stada.com/investor-relations